Innate Pharma announces Nectin-4 antibody drug conjugate investor and analyst event in New York

• Innate Pharma to highlight IPH4502, its lead Nectin-4 Antibody Drug Conjugate (ADC) program at clinical stage

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) will host an event for institutional investors and analysts dedicated to its Antibody-Drug Conjugate (ADC) strategy, and particularly Nectin-4, the target of its lead antibody-drug candidate program, IPH4502. The event will be held in New York in a hybrid format on Wednesday, February 5, 2025, from 10:00 a.m. to 12:00 p.m. EDT.

“As we just updated our strategy with a focus on our ANKET® platform and ADC programs, this conference will be an opportunity to share the latest scientific and clinical advancements related to Nectin-4 and its potential in cancer treatment,” said Jonathan Dickinson, Chief Executive Officer of Innate Pharma

Event details:

• Date: February 5, 2025, from 10:00 a.m. to 12:00 p.m. EDT 
• Registration: If you would like to attend the event, please register at this link: https://form.jotform.com/250134241556348

For those who are unable to attend in person, a live webcast and replay will be on Innate Pharma’s website at: https://www.innate-pharma.com.

Click here to download the presentation.

About IPH4502

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion molecule that is overexpressed in several types of solid tumors, including urothelial carcinoma, where Nectin-4 expression is highest, breast cancer, non-small cell lung cancer and gastro-intestinal cancer.

In non-clinical models, IPH45 is well tolerated and shows anti-tumor activity in vitro and in vivo. 

In September 2024, the U.S Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to initiate a Phase 1 clinical study of IPH4502.